NO20044673L - Farmasoytisk kombinasjon - Google Patents

Farmasoytisk kombinasjon

Info

Publication number
NO20044673L
NO20044673L NO20044673A NO20044673A NO20044673L NO 20044673 L NO20044673 L NO 20044673L NO 20044673 A NO20044673 A NO 20044673A NO 20044673 A NO20044673 A NO 20044673A NO 20044673 L NO20044673 L NO 20044673L
Authority
NO
Norway
Prior art keywords
compound
pharmaceutical combination
pharmaceutically acceptable
derivative
arrhythmia
Prior art date
Application number
NO20044673A
Other languages
English (en)
Inventor
Elisabeth Svernhage
Ann-Charlotte Roth-Rosendahl
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20044673L publication Critical patent/NO20044673L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Det er tilveiebragt et kombinasjonsprodukt omfattende: (1) en forbindelse ifølge krav I i WO 02/44145 eller en forbindelse ifølge krav 20 i WO 02/44145 (eller derivat derav) eller et farmasøytisk akseptabelt derivat derav; og (1) en forbindelse som definert i krav I i WO 01/28992 eller (2) en forbindelse ifølge krav 34 i WO 01/28992 eller (3) Forbindelse A eller B eller C eller D (eller farmasøytisk akseptable salter derav) for anvendelse ved behandling av arrytmi eller en koaguleringskontrollert komplikasjon derav.
NO20044673A 2002-05-31 2004-10-28 Farmasoytisk kombinasjon NO20044673L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0201662A SE0201662D0 (sv) 2002-05-31 2002-05-31 Pharmaceutical combination
PCT/SE2003/000854 WO2003101956A1 (en) 2002-05-31 2003-05-27 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
NO20044673L true NO20044673L (no) 2004-12-07

Family

ID=20288040

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20044673A NO20044673L (no) 2002-05-31 2004-10-28 Farmasoytisk kombinasjon

Country Status (19)

Country Link
US (1) US20060052314A1 (no)
EP (1) EP1513807A1 (no)
JP (1) JP2005532345A (no)
CN (1) CN1656066A (no)
AR (1) AR040138A1 (no)
AU (1) AU2003232711A1 (no)
BR (1) BR0311138A (no)
CA (1) CA2486110A1 (no)
CO (1) CO5631429A2 (no)
IL (1) IL165169A0 (no)
IS (1) IS7581A (no)
MX (1) MXPA04011910A (no)
NO (1) NO20044673L (no)
PL (1) PL373409A1 (no)
RU (1) RU2004131868A (no)
SE (1) SE0201662D0 (no)
TW (1) TW200307686A (no)
WO (1) WO2003101956A1 (no)
ZA (1) ZA200408787B (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401539D0 (sv) 2004-06-15 2004-06-15 Astrazeneca Ab New compounds
KR20080021114A (ko) 2005-06-13 2008-03-06 아스트라제네카 아베 심부정맥의 치료를 위한 신규한 옥사비스피딘 화합물
WO2006137772A1 (en) * 2005-06-20 2006-12-28 Astrazeneca Ab New physical form of n,n´- disubstituted oxabispidines
JP5114880B2 (ja) 2006-07-06 2013-01-09 ダイキン工業株式会社 新規α−フルオロメトキシカルボン酸エステル、該α−フルオロメトキシカルボン酸エステルの製造方法及びセボフルランの製造方法
US9802954B2 (en) 2011-08-24 2017-10-31 Boehringer Ingelheim International Gmbh Piperidino-dihydrothienopyrimidine sulfoxides and their use for treating COPD and asthma
CN108314624B (zh) * 2017-01-17 2022-09-27 东莞东阳光科研发有限公司 一种多氟苯胺的制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903759D0 (sv) * 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios

Also Published As

Publication number Publication date
RU2004131868A (ru) 2005-10-10
AU2003232711A1 (en) 2003-12-19
CN1656066A (zh) 2005-08-17
MXPA04011910A (es) 2005-03-31
WO2003101956A1 (en) 2003-12-11
TW200307686A (en) 2003-12-16
SE0201662D0 (sv) 2002-05-31
CO5631429A2 (es) 2006-04-28
CA2486110A1 (en) 2003-12-11
BR0311138A (pt) 2005-03-01
JP2005532345A (ja) 2005-10-27
PL373409A1 (en) 2005-08-22
US20060052314A1 (en) 2006-03-09
IL165169A0 (en) 2005-12-18
EP1513807A1 (en) 2005-03-16
IS7581A (is) 2004-12-03
ZA200408787B (en) 2005-10-20
AR040138A1 (es) 2005-03-16

Similar Documents

Publication Publication Date Title
GEP20043269B (en) Purine Derivatives, Method for Their Production and Composition Containing the Same
NO20065904L (no) Terapeutiske forbindelser
NO20080164L (no) N-(pyridin-2-yl)-sulfonamidderivater
NO20065878L (no) Terapeutiske forbindelser
NO20060147L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20050579L (no) Indolinfenylsulfonamidderivater
NO20061839L (no) Benzimidazolderivater, sammensetninger inneholdende dem, fremstilling derav, og anvendelse derav
CA2478374A1 (en) N3 alkylated benzimidazole derivatives as mek inhibitors
NO20054852L (no) GFAT inhibitorer
NO20035210L (no) 2-anilino-pyrimidinderivater som cyklinavhengige kinaseinhibitorer
NO20041041L (no) Fenetanolaminderivater for behandling av respiratoriske sykdommer
ATE386725T1 (de) Heterocyclylverbindungen
AU2002239830A1 (en) Pyruvate cardioplegia solutions for administration to the heart during cardiopulmonary surgery and methods of use thereof
ATE212837T1 (de) Pharmazeutische zubereitung zur behandlung akuter rhinitiden, enthaltend sympthomimeticum und pantothenol und/oder pantothensäure
NO20050771L (no) Bicifadinformulering
NO20044673L (no) Farmasoytisk kombinasjon
NO20044689L (no) (2-((2alkoksy)-fenyl)-cyklopent-1-enyl)aromatisk karbo og heterocyklisk syre og derivater
NO20052313L (no) Vandig farmasoytisk formulering omfattende trombininhibitorer melagatran og anvendelse av formuleringen for fremstilling av et medikament for anvendelse i nasal administrering i behandling av
ATE236885T1 (de) Hydrazono-benzazulen-derivate, pharmazeutische zusammensetzungen und zwischenprodukte
NO20013921L (no) Heterocykliske derivater som inhibitorer av faktor Xa
NO20044554L (no) Kombinasjonsprodukt omfattende melagatran og anti-arrytmiske oksabispidener
HK1075654A1 (en) Hyperforin derivatives, the use thereof and formulations containing them
NO20044555L (no) Kombinasjonsprodukt omfattende en antikoagulant og anti-arrytmiske oksabispidener
AR042199A1 (es) Composicion farmaceutica liquida que comprende una cantidad terapeuticamente eficaz de al menos un compuesto de 3,7 diazabiciclo (3,3,1) nonano, metodo de tratamiento y/o profilaxis de eventos anti-arritmicos en seres humanos y producto y/o forma de presentacion farmaceutica
AR009446A1 (es) Utilizacion del acido 2-(3,4-dimetoxinamoil)aminobenzoico (tranilast) en la fabricacion de un medicamento para el tratamiento o prevencion de larestenosis, composicion farmaceutica y procedimiento de preparacion.